BARCLAYS
7.9.2022 09:01:53 CEST | Business Wire | Press release
Barclays has appointed Daniel Hanna as Global Head of Sustainable Finance for the Corporate and Investment Bank with the responsibility for creating a market-leading center of excellence for sustainable finance. He will be based in London and joins the Corporate and Investment Bank’s Management Committee.
“The center of excellence will bring together the power of our 'One Barclays' approach to deliver a fuller suite of products, solutions, and expertise to clients as they navigate the transition to a low-carbon economy,” said Paul Compton, Global Head of Corporate and Investment Bank and President, Barclays Bank Plc. “He will partner closely with the Sustainable Capital Markets, Sustainable and Impact Banking, and the Sustainable Product Group teams, as well as with Barclays’ Sustainability and ESG team to ensure connectivity with Barclays’ broader firm-wide efforts.”
“We are focused on the delivery of our climate strategy, including capturing new opportunities to deepen client relationships and create new growth for Barclays’ businesses,” said Sasha Wiggins, Barclays’ Group Head of Public Policy and Corporate Responsibility. “Whilst we are already using our expertise across our Corporate and Investment Bank to help clients manage this period of extraordinary change, Daniel’s appointment gives us a powerful focus to create a real point of difference with clients.”
Mr. Hanna joins Barclays from Standard Chartered, where he was most recently Global Head of Sustainable Finance.
“Barclays was one of the first banks to commit to net zero by 2050 and has a fantastic track record of innovation in green and sustainable finance,” said Mr. Hanna. “As the world deals with the impact of high energy prices and climate change, Barclays has a strong platform to help channel capital to the new technologies, and companies, that can help economies decarbonize and drive sustainable growth.”
The transition to a low carbon economy is today’s defining opportunity for innovation and growth - supporting clients in their efforts to decarbonise and adapt their business models is a strategic priority at Barclays. There is a significant opportunity for Barclays to play a leading role in helping to meet the demand for financing to support the energy transition, channelling investment into new green technologies and low-carbon infrastructure projects. Barclays has already facilitated £74bn of green financing, including landmark projects such as supporting the UK Government to issue their first green bond, which will finance projects such as offshore wind and schemes to decarbonise homes and buildings. To find out more about Barclays’ approach to climate change, please visit our website.
About Barclays
Barclays is a British universal bank. We are diversified by business, by different types of customer and client, and geography. Our businesses include consumer banking and payments operations around the world, as well as a top-tier, full service, global corporate and investment bank, all of which are supported by our service company which provides technology, operations and functional services across the Barclays Group. For further information about Barclays, please visit our website home.barclays.
About Barclays Corporate and Investment Bank
Barclays is a consumer and wholesale bank, supporting individuals and small businesses through our consumer banking services, and larger businesses and institutions through our corporate and investment banking services. Our Corporate and Investment Bank is comprised of the Investment Banking, International Corporate Banking, Global Markets and Research businesses; it provides money managers, financial institutions, governments, supranational organisations and corporate clients with services and advice for their funding, financing, strategic and risk management needs. For further information about Barclays Corporate and Investment Bank, please visit our website www.cib.barclays.
About Barclays Commitment to Address Climate Change
In March 2020, Barclays announced an ambition to be a net zero bank by 2050, becoming one of the first banks to do so. Barclays is working to achieve net zero operations, investing in the continued decarbonisation of our operations, and in the development of a net zero pathway for the emissions from our supply chain. Barclays is also committed to aligning its financing with the goals and timelines of the Paris Agreement and to providing the green and sustainable finance required to transform the economies it serves.
About Barclays’ Sustainable Capital Markets (SCM) Team
Barclays’ Sustainable Capital Markets (SCM) team offers a broad range of ESG capital market product types and delivers across multiple client segments to help clients finance their sustainability journeys and formalise their sustainability commitments.
About Barclays’ Sustainable and Impact Banking (SIB) Team
Barclays’ Sustainable and Impact Banking (SIB) team advises and raises capital for emerging growth companies that are addressing ESG issues, as well as for existing clients navigating their energy transitions.
About Barclays’ Sustainable Product Group (SPG) Team
Barclays’ Sustainable Product Group (SPG) team offers a set of green products based on Barclays Green Finance Framework, including Green Innovation Finance, Green Loans, Green Asset Finance, Green Trade Finance, Green Infrastructure and Project Finance, and Green Deposits.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005147/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom